title: Therapies in development for the treatment of migraine.
abstract: While oral formulations of agonists at the serotonin (5-HT) receptor subdivisions 5-HT(1B/1D)--the "triptan" class of drugs--dominate the market for migraine therapy and while still more triptans are under development, recent research efforts have also explored other pharmacological avenues, which are mostly based on our extended insights into the neuropathology and genetics of migraine. Genetic research, in particular, continues to reveal new potential drug targets, indicating that the migraine treatment options that may become available by 2010 might be substantially different from today's scenery. Meanwhile, pharmaceutical companies make increasing use of drug delivery and formulation technologies to improve the action profile and convenience of use for current triptans and this has even led to a partial revival of "old" migraine drugs, such as ergot alkaloids. The broadest potential, however, lies in a better understanding of the molecular pharmacology of migraine.
authors.affiliation: HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Vienna, Austria. h.mucke@hmpharmacon.com
authors.forename: Hermann
authors.initials: H
authors.lastname: Mucke
mesh_terms: D016503:Drug Delivery Systems; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D009570:Nitriles / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D014363:Tryptamines
chemical_list: D009570:Nitriles; D010879:Piperazines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C120143:donitriptan